Download Files:
KAG-308
$1,650 – $8,700
Products Details
Product Description
– KAG-308 is a potent selective and orally active agonist of EP4 receptor (a prostaglandin E2 receptor subtype), suppresses colitis and promotes histological mucosal healing, potently inhibits TNF-α production. KAG-308 shows a Ki and an EC50 of 2.57 nM and 17 nM for human EP4 receptor, respectively, more selective over EP1, EP2, EP3 and IP receptor[1].
Web ID
– HY-128686
Storage Temperature
– -20°C (Powder, stored under nitrogen)
Shipping
– Blue Ice
Applications
– COVID-19-immunoregulation
Molecular Formula
– C24H30F2N4O3
References
– [1]Watanabe Y, et al. KAG-308, a newly-identified EP4-selective agonist shows efficacy for treating ulcerative colitis and can bring about lower risk of colorectal carcinogenesis by oral administration. Eur J Pharmacol. 2015 May 5;754:179-89.
CAS Number
– 1215192-68-9
Molecular Weight
– 460.52
Compound Purity
– 99.64
SMILES
– O[C@H](C1)[C@H](/C=C/[C@@H](O)[C@@H](C2=CC=CC(C)=C2)C)[C@](C/3(F)F)([H])[C@@]1([H])OC3=C/CCCC4=NN=NN4
Clinical Information
– No Development Reported
Research Area
– Inflammation/Immunology; Endocrinology
Solubility
– |DMSO : 80 mg/mL (ultrasonic)
Target
– Prostaglandin Receptor
Isoform
– EP
Pathway
– GPCR/G Protein
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
